Exploring the Crosstalk Between Inflammation and Epithelial-Mesenchymal Transition in Cancer

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2021 Jul 5

PMID 34220337

Citations 40

Authors

Indranil Chattopadhyay

Rangarao Ambati

Rohit Gundamaraju

Affiliations

Soon will be listed here.

Abstract

Tumor cells undergo invasion and metastasis through epithelial-to-mesenchymal cell transition (EMT) by activation of alterations in extracellular matrix (ECM) protein-encoding genes, enzymes responsible for the breakdown of ECM, and activation of genes that drive the transformation of the epithelial cell to the mesenchymal type. Inflammatory cytokines such as TGF, TNF, IL-1, IL-6, and IL-8 activate transcription factors such as Smads, NF-B, STAT3, Snail, Twist, and Zeb that drive EMT. EMT drives primary tumors to metastasize in different parts of the body. T and B cells, dendritic cells (DCs), and tumor-associated macrophages (TAMs) which are present in the tumor microenvironment induce EMT. The current review elucidates the interaction between EMT tumor cells and immune cells under the microenvironment. Such complex interactions provide a better understanding of tumor angiogenesis and metastasis and in defining the aggressiveness of the primary tumors. Anti-inflammatory molecules in this context may open new therapeutic options for the better treatment of tumor progression. Targeting EMT and the related mechanisms by utilizing natural compounds may be an important and safe therapeutic alternative in the treatment of tumor growth.

Citing Articles

The Role of Epithelial-Mesenchymal Transition in Osteosarcoma Progression: From Biology to Therapy.

Patrascu A, Tarca E, Lozneanu L, Ungureanu C, Morosan E, Parteni D Diagnostics (Basel). 2025; 15(5).

PMID: 40075892 PMC: 11898898. DOI: 10.3390/diagnostics15050644.

Respiratory Distress Arising from a Peripheral Osteoma: A Rare Case Report.

Patil K, Sanjay C, Christopher V, Solayappan E Indian J Otolaryngol Head Neck Surg. 2025; 77(1):495-499.

PMID: 40066411 PMC: 11890650. DOI: 10.1007/s12070-024-05150-4.

CD109, a master regulator of inflammatory responses.

Batal A, Garousi S, Finnson K, Philip A Front Immunol. 2025; 15:1505008.

PMID: 39990858 PMC: 11842317. DOI: 10.3389/fimmu.2024.1505008.

Exploring the Role of Epithelial-Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review.

Kanwal R, Esposito J, Jawed B, Zakir S, Pulcini R, Martinotti R Cancers (Basel). 2025; 17(3).

PMID: 39941895 PMC: 11817253. DOI: 10.3390/cancers17030529.

Exploring the tumor-suppressive role of miRNA-200c in head and neck squamous cell carcinoma: Potential and mechanisms of exosome-mediated delivery for therapeutic applications.

Kishta M, Khamis A, Am H, Elshaar A, Gul D Transl Oncol. 2024; 51:102216.

PMID: 39615277 PMC: 11647223. DOI: 10.1016/j.tranon.2024.102216.

References

Fernando R, Castillo M, Litzinger M, Hamilton D, Palena C . IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011; 71(15):5296-306. PMC: 3148346. DOI: 10.1158/0008-5472.CAN-11-0156. View

Chung H, Choi H, Seo E, Kang D, Oh E . Baicalin and baicalein inhibit transforming growth factor-β1-mediated epithelial-mesenchymal transition in human breast epithelial cells. Biochem Biophys Res Commun. 2015; 458(3):707-713. DOI: 10.1016/j.bbrc.2015.02.032. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Chen W, Ten Dijke P . Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol. 2016; 16(12):723-740. DOI: 10.1038/nri.2016.112. View

Vincent T, Neve E, Johnson J, Kukalev A, Rojo F, Albanell J . A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009; 11(8):943-50. PMC: 3769970. DOI: 10.1038/ncb1905. View

Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y . Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016; 22(14):3630-42. PMC: 4947453. DOI: 10.1158/1078-0432.CCR-15-1434. View

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Mann M, Mehta A, Zhao J, Lee K, Marinov G, Garcia-Flores Y . An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017; 8(1):851. PMC: 5636846. DOI: 10.1038/s41467-017-00972-z. View

Zhang L, Wang D, Li Y, Liu Y, Xie X, Wu Y . CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway. PLoS One. 2016; 11(8):e0158529. PMC: 4978474. DOI: 10.1371/journal.pone.0158529. View

10.

Vergara D, Valente C, Tinelli A, Siciliano C, Lorusso V, Acierno R . Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 2011; 310(1):1-8. DOI: 10.1016/j.canlet.2011.04.009. View

11.

Kapur N, Mir H, Clark Iii C, Krishnamurti U, Beech D, Lillard J . CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016; 114(12):1343-51. PMC: 4984452. DOI: 10.1038/bjc.2016.113. View

12.

Fuxe J, Karlsson M . TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012; 22(5-6):455-61. DOI: 10.1016/j.semcancer.2012.05.004. View

13.

Thillainadesan G, Chitilian J, Isovic M, Ablack J, Mymryk J, Tini M . TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. Mol Cell. 2012; 46(5):636-49. DOI: 10.1016/j.molcel.2012.03.027. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T . Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011; 11:130. PMC: 3095565. DOI: 10.1186/1471-2407-11-130. View

16.

Mariani F, Sena P, Roncucci L . Inflammatory pathways in the early steps of colorectal cancer development. World J Gastroenterol. 2014; 20(29):9716-31. PMC: 4123361. DOI: 10.3748/wjg.v20.i29.9716. View

17.

Avila-Carrasco L, Majano P, Sanchez-Tomero J, Selgas R, Lopez-Cabrera M, Aguilera A . Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition. Front Pharmacol. 2019; 10:715. PMC: 6682706. DOI: 10.3389/fphar.2019.00715. View

18.

Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L . CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2015; 55(11):1688-1699. PMC: 5057350. DOI: 10.1002/mc.22419. View

19.

Visciano C, Liotti F, Prevete N, Cali G, Franco R, Collina F . Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene. 2015; 34(40):5175-86. DOI: 10.1038/onc.2014.441. View

20.

Browning L, Patel M, Horvath E, Tawara K, Jorcyk C . IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018; 10:6685-6693. PMC: 6287645. DOI: 10.2147/CMAR.S179189. View